Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 18;42(1):60.
doi: 10.1186/s13052-016-0267-2.

Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study

Liviana Da Dalt  1 , Claudia Zerbinati  2 , Maria Stefania Strafella  2 , Salvatore Renna  3 , Laura Riceputi  3 , Pasquale Di Pietro  3 , Paola Barabino  3 , Stefania Scanferla  1 , Umberto Raucci  4 , Nadia Mores  5 , Adele Compagnone  5 , Roberto Da Cas  6 , Francesca Menniti-Ippolito  7 ; Italian Multicenter Study Group for Drug and Vaccine Safety in Children
Collaborators, Affiliations

Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study

Liviana Da Dalt et al. Ital J Pediatr. .

Abstract

Background: Henoch-Schönlein purpura (HSP) is the most common vasculitis in childhood; nevertheless, its etiology and pathogenesis remain unknown despite the fact that a variety of factors, mainly infectious agents, drugs and vaccines have been suggested as triggers for the disease. The aim of this study was to estimate the association of HSP with drug and vaccine administration in a pediatric population.

Methods: An active surveillance on drug and vaccine safety in children is ongoing in 11 clinical centers in Italy. All children hospitalized through the local Paediatric Emergency Department for selected acute clinical conditions of interest were enrolled in the study. Data on drug and vaccine use in children before the onset of symptoms leading to hospitalization were collected by parents interview. A case-control design was applied for risk estimates: exposure in children with HSP, included as cases, was compared with similar exposure in children with gastroduodenal lesions, enrolled as controls. HSP cases were validated according to EULAR/PRINTO/PRES criteria. Validation was conducted retrieving data from individual patient clinical record.

Results: During the study period (November 1999-April 2013), 288 cases and 617 controls were included. No increased risk of HSP was estimated for any drug. Among vaccines, measles-mumps-rubella (MMR) vaccine showed an increased risk of HSP (OR 3.4; 95 % CI 1.2-10.0).

Conclusions: This study provides further evidence on the possible role of MMR vaccine in HSP occurrence.

Keywords: Adverse drug reaction; Children; Henoch-Schönlein purpura; Vaccine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Enrollment, retrieving and validation process of HSP patients
See this image and copyright information in PMC

References

    1. Trnka P. Henoch-Schonlein purpura in children. J Paediatr Child Health. 2013;49(12):995–1003. doi: 10.1111/jpc.12403. - DOI - PubMed
    1. McCarthy HJ, Tizard EJ. Clinical practice: Diagnosis and management of Henoch-Schönlein purpura. Eur J Pediatr. 2010;169(6):643–50. doi: 10.1007/s00431-009-1101-2. - DOI - PubMed
    1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi: 10.1002/art.37715. - DOI - PubMed
    1. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69(5):798–806. doi: 10.1136/ard.2009.116657. - DOI - PubMed
    1. Saulsubry FT. Henoch-Schönlein purpura. Curr Opin Rheumatol. 2001;13(1):35–40. doi: 10.1097/00002281-200101000-00006. - DOI - PubMed

MeSH terms

Substances